BioCryst Pharmaceuticals Inc (BCRX) stock saw a decline, ending the day at $7.64 which represents a decrease of $-0.09 or -1.16% from the prior close of $7.73. The stock opened at $7.64 and touched a ...

BioCryst Pharmaceuticals Inc (BCRX) stock saw a modest uptick, ending the day at $7.73 which represents a slight increase of $0.11 or 1.44% from the prior close of $7.62. The stock opened at $7.58 and ...

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) has been given an average recommendation of “Moderate Buy” by ...

RBC Capital analyst Brian Abrahams maintained a Buy rating on BioCryst (BCRX – Research Report) on January 21 and set a price target of $10.00.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to ...

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) unveiled its preliminary, unaudited ORLADEYO® (berotralstat) net revenue and total revenue figures for the fourth quarter and full fiscal year that ...

Hidden gems in the biotech sector are reshaping healthcare with breakthroughs in personalized medicine and rare disease ...

and Current Reports on Form 8-K, which identify important factors that could cause actual results to differ materially from those contained in BioCryst’s projections and forward-looking statements.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares are flat Monday after the company reported its fourth-quarter financial results before the opening bell. The Details: BioCryst reported ...

RESEARCH TRIANGLE PARK, N.C., Jan. 10, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced preliminary, unaudited ORLADEYO ...